Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Launched by PRICE VISION GROUP · Aug 7, 2019
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 18 years of age
- • Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam and/or corneal tomography.
- • Patient is able and willing to administer eye drops.
- • Patient is able to comprehend and has signed the Informed Consent form.
- Exclusion Criteria:
- • Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.
- • Known sensitivity to any of the ingredients in the study medications.
- • Abnormal eyelid function.
- • History of herpetic keratitis.
- • History of non-compliance with using prescribed medication.
- • Current or planned pregnancy within the study duration.
- • Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study.
- • Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.
About Price Vision Group
Price Vision Group is a leading clinical trial sponsor specializing in innovative ophthalmic research and development. With a commitment to advancing eye care, the organization conducts rigorous clinical studies aimed at enhancing vision-related outcomes through groundbreaking therapies and technologies. Leveraging a multidisciplinary team of experts, Price Vision Group collaborates with healthcare professionals and research institutions to ensure the highest standards of scientific integrity and patient safety. Their focus on patient-centric approaches and cutting-edge research positions them at the forefront of the evolving landscape of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Indianapolis, Indiana, United States
Patients applied
Trial Officials
Francis W Price, Jr, MD
Principal Investigator
Price Vision Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials